1. Home
  2. ACHV vs TLSA Comparison

ACHV vs TLSA Comparison

Compare ACHV & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACHV
  • TLSA
  • Stock Information
  • Founded
  • ACHV N/A
  • TLSA 2013
  • Country
  • ACHV United States
  • TLSA United Kingdom
  • Employees
  • ACHV N/A
  • TLSA N/A
  • Industry
  • ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • TLSA Biotechnology: Pharmaceutical Preparations
  • Sector
  • ACHV Health Care
  • TLSA Health Care
  • Exchange
  • ACHV Nasdaq
  • TLSA Nasdaq
  • Market Cap
  • ACHV 167.6M
  • TLSA 187.0M
  • IPO Year
  • ACHV N/A
  • TLSA 2000
  • Fundamental
  • Price
  • ACHV $3.17
  • TLSA $2.14
  • Analyst Decision
  • ACHV Strong Buy
  • TLSA
  • Analyst Count
  • ACHV 1
  • TLSA 0
  • Target Price
  • ACHV $12.00
  • TLSA N/A
  • AVG Volume (30 Days)
  • ACHV 727.0K
  • TLSA 441.4K
  • Earning Date
  • ACHV 11-06-2025
  • TLSA 05-06-2025
  • Dividend Yield
  • ACHV N/A
  • TLSA N/A
  • EPS Growth
  • ACHV N/A
  • TLSA N/A
  • EPS
  • ACHV N/A
  • TLSA N/A
  • Revenue
  • ACHV N/A
  • TLSA N/A
  • Revenue This Year
  • ACHV N/A
  • TLSA N/A
  • Revenue Next Year
  • ACHV N/A
  • TLSA N/A
  • P/E Ratio
  • ACHV N/A
  • TLSA N/A
  • Revenue Growth
  • ACHV N/A
  • TLSA N/A
  • 52 Week Low
  • ACHV $1.84
  • TLSA $0.63
  • 52 Week High
  • ACHV $5.31
  • TLSA $2.60
  • Technical
  • Relative Strength Index (RSI)
  • ACHV 51.96
  • TLSA 56.23
  • Support Level
  • ACHV $3.07
  • TLSA $1.95
  • Resistance Level
  • ACHV $3.48
  • TLSA $2.33
  • Average True Range (ATR)
  • ACHV 0.15
  • TLSA 0.20
  • MACD
  • ACHV -0.01
  • TLSA 0.01
  • Stochastic Oscillator
  • ACHV 34.85
  • TLSA 48.88

About ACHV Achieve Life Sciences Inc.

Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.

Share on Social Networks: